Second cancer after additive chemotherapy in patients with colon cancer: original study
Background - Additive chemotherapeutic treatment of UICC-stage -III / IV colon cancer with fluorouracil, leucovorin and oxaliplatin is widely accepted as current standard of treatment after R0-resection. However, as patients.. survival is increasing, long-term side effects of chemotherapeutic agents...
Gespeichert in:
| Hauptverfasser: | , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
29 November 2022
|
| In: |
Clinical colorectal cancer and other gastrointestinal malignancies
Year: 2022, Jahrgang: 21, Heft: 4, Pages: 354-361 |
| ISSN: | 1938-0674 |
| DOI: | 10.1016/j.clcc.2022.07.002 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.clcc.2022.07.002 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S1533002822000706 
|
| Verfasserangaben: | Andreas Teufel, Moying Li, Michael Gerken, Matthias P. Ebert, Hans J Schlitt, Matthias Evert, Wolfgang Herr, Monika Klinkhammer-Schalke |
| Zusammenfassung: | Background - Additive chemotherapeutic treatment of UICC-stage -III / IV colon cancer with fluorouracil, leucovorin and oxaliplatin is widely accepted as current standard of treatment after R0-resection. However, as patients.. survival is increasing, long-term side effects of chemotherapeutic agents such as second cancer development are becoming increasingly important. - Patients - We therefore investigated a total of 2 856 Patients with UICC-stage III / IV colon cancer, 223 of whom (7.8%) had developed a subsequent second cancer. - Results - Median follow-up was 73.2 months (range 209.9 months, 95%-CI 69.8-76.9). Most frequent second cancers were prostate cancer (18.4%), colon cancer (16.1%), breast cancers (8.1%), lung cancer (8.1%), rectal cancer (4.9%) and uterine cancer (4.9%). However, in comparison to non-treated patients this did not represent a significantly increased risk for subsequent second cancer in patients after treatment with additive chemotherapy. Of interest, our data suggest a significantly decreased second cancer rate in patients treated with FOLFOX compared to FUFOL for additive treatment. - Conclusions - Second cancer development was not increased after additive chemotherapy for colon cancer, which is a novel aspect in the ongoing discussions on reduction of adjuvant treatment to 3 months or treatment of lymph node negative patients. Novelty and Impact Statement To our knowledge, this is the first population-based study analyzing second cancer development after additive chemotherapy in patients with UICC III-IV colon cancer. The results have an important impact on the surveillance and long-term follow-up of cancer patients. |
|---|---|
| Beschreibung: | Online verfügbar: 16 July 2022, Artikelversion: 29 November 2022 Gesehen am 26.06.2023 |
| Beschreibung: | Online Resource |
| ISSN: | 1938-0674 |
| DOI: | 10.1016/j.clcc.2022.07.002 |